COMP <GO>
PTCT vs ABBV // FREE CASH FLOW YIELD
PTC Therapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: PTCT 8
— ABBV 5
▲ FREE CASH FLOW YIELD LEADER: PTCT
LAST: $59.97 (-6.97%) • MKT CAP: $5.38B
fcf-yield
13.05%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTCT VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTCT | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 29.00% | +56.00 | PTCT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.5x | 33.3x | -26.80 | PTCT | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 13.05% | 3.47% | +9.58 | PTCT | /fcf-yield <GO> |
| Operating Margin | 50.10% | 24.60% | +25.50 | PTCT | /operating-margins <GO> |
| Net Profit Margin | 39.50% | 6.90% | +32.60 | PTCT | /net-margins <GO> |
| Revenue Growth (YoY) | 114.50% | 8.60% | +105.90 | PTCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.73 | 5.33 | -3.60 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | PTCT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.40% | 7.40% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.5 | 72.8 | -31.24 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.15 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.6x | 113.1x | -106.50 | PTCT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.38B | $513.86B | -$508.48B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTCT REV | ABBV REV | PTCT GROSS % | ABBV GROSS % | PTCT FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.73B | $61.16B | 44.0% | 70.2% | $702.3M | $17.82B |
| FY 2024 | $806.8M | $56.33B | 44.0% | 70.0% | -$114.2M | $17.83B |
| FY 2023 | $937.8M | $54.32B | 44.0% | 44.0% | -$200.6M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTCT // BETA 1.15
ABBV // BETA 1.15